Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06719089

Evaluation of the Safety and Performance of the Hydrustent® Biodegradable Hydrogel Ureteral Stent

Led by Hydrumedical · Updated on 2026-04-29

134

Participants Needed

4

Research Sites

68 weeks

Total Duration

On this page

Sponsors

H

Hydrumedical

Lead Sponsor

B

Blueclinical, Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical investigation is to evaluate whether the Hydrustent® medical device is safe and if maintain the urinary flow inside the ureter in adults. The main questions it aim to answer are: * Does Hydrustent® maintain urinary patency post-surgery in adults? * What medical issues do participants experience while using Hydrustent®? Researchers will compare the Hydrustent® medical device to a comparator (a standard medical device used in clinical practice) to determine whether Hydrustent® is at least non-inferior in terms of safety and efficacy. Other questions that the study will answer are: * Does Hydrustent® exhibit a durability of at least 24 hours? * Does Hydrustent® prevents the need of the surgical procedure to remove the ureteral stent? * Does Hydrustent® reduce urinary symptoms associated with a ureteral stent? Participants will: * Have either the Hydrustent® or a comparator device inserted following the removal of ureteral or renal stones via endourological techniques. * Be monitored for 3 months post-surgery through regular follow-up visits. * Complete questionnaires and undergo imaging exams, as well as blood and urine analyses to assess recovery.

CONDITIONS

Official Title

Evaluation of the Safety and Performance of the Hydrustent® Biodegradable Hydrogel Ureteral Stent

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged between 18 and 70 years (pilot phase) or older than 18 years (pivotal phase)
  • Able to understand study requirements and provide written or oral informed consent
  • Have ureteral and/or renal stones and have undergone successful, uncomplicated unilateral ureteroscopy and/or retrograde intra-renal surgery
  • Have body size suitable for a 22 to 28 cm long, 7 Fr diameter ureteral stent
  • Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception during the study
  • Male participants must agree to refrain from semen donation during the study
Not Eligible

You will not qualify if you...

  • Urinary tract anatomical malformations or prior significant urinary surgery
  • Known or suspected urothelial or renal tumors
  • Known or suspected extrinsic ureteral compression or strictures
  • Known or suspected ureteral perforation or fistula
  • Active treatment for bladder outlet obstruction, neurogenic bladder, overactive bladder, or urge urinary incontinence
  • Solitary kidney
  • Glomerular filtration rate below 60 mL/min/1.73m2
  • Known renal insufficiency or chronic impairment
  • Incomplete stone fragmentation requiring additional procedure
  • Active bleeding disorders or current anticoagulant use (except antiplatelet agents)
  • Pre-operative evidence of staghorn calculi
  • Active or suspected urinary tract infection or positive urine culture at time of stent placement
  • Allergy to contrast agents
  • Pregnant, lactating, or women of childbearing potential not using highly effective contraception
  • Severe psychiatric disorders, substance abuse, or inability to comply with study procedures
  • Signs of acute or chronic infections
  • Sensitivity or allergy to implant materials
  • Ureteral blockage or strictures
  • Failed guidewire placement or ureteroscopy access
  • Suspected ureteral avulsion
  • Untreated infected urinary obstruction (pyonephrosis)
  • Vascular abnormalities of renal pelvis outlet
  • Unexplained blood in urine
  • Significant urethral obstruction
  • Untreated bladder stones
  • Participation in another investigational study
  • Any other condition making the participant ineligible according to the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Unidade Local de Saúde da Região de Aveiro (ULSRA), E.P.E.

Aveiro, Aveiro District, Portugal, 3814-501

Actively Recruiting

2

Unidade Local de Unidade Local de Saúde do Alto Ave (ULSAAVE), E.P.E

Guimarães, Braga District, Portugal, 4835-044

Actively Recruiting

3

Hospital CUF Tejo

Lisbon, Portugal, 1350-352

Not Yet Recruiting

4

Unidade Local de Saúde do Alto Minho (ULSAM)

Viana do Castelo, Portugal, 4904-858

Not Yet Recruiting

Loading map...

Research Team

F

Ferreira (Sponsor)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here